Recent advances in the molecular understanding of glioblastoma
Top Cited Papers
Open Access
- 20 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 108 (1), 11-27
- https://doi.org/10.1007/s11060-011-0793-0
Abstract
Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor’s resistance to current therapeutic approaches. Thus far, methylation of the O 6-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel “genome-wide” techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma.Keywords
This publication has 125 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in GlioblastomaCancer Cell, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastomaActa Neuropathologica, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in GlioblastomasJama-Journal Of The American Medical Association, 2009
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial CellsCancer Cell, 2008
- Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma DevelopmentCancer Cell, 2008